Education
About Us
Working with TipRanks
Follow Us
Zentek (TSE:ZEN)
:ZEN
ZEN Stock Chart & Stats
C$1.02
C$0.00(0.00%)
At close: 4:00 PM EST
C$1.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.75 - C$2.50
Previous CloseN/A
Volume4.47K
Average Volume (3M)66.24K
Market Cap
C$83.70M
Enterprise ValueC$85.96M
Total Cash (Recent Filing)C$1.80M
Total Debt (Recent Filing)C$1.92M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding107,306,500
10 Day Avg. Volume86,681
30 Day Avg. Volume66,239
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)11.24
Price to Sales (P/S)190.02
P/FCF Ratio-26.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage, Solid Balance SheetDebt-to-equity is reported well below 0.2 and total assets are meaningful relative to the revenue base, giving Zentek financial flexibility. Over a 2–6 month horizon this reduces short-term solvency risk, supports R&D or pilot manufacturing spend, and preserves optionality for partnerships or licensing.
Rapid Revenue GrowthDespite a small absolute base, the extremely high reported revenue growth indicates accelerating top-line traction from R&D commercialization or new contracts. If that growth trend persists, it can support improving operating leverage and margin recovery over the medium term and reduce dependence on external funding.
Proprietary Graphene / Nanotech R&D And IPZentek's focus on graphene and nanotechnology with applications like antimicrobial coatings reflects durable structural demand in advanced materials. Ongoing R&D and IP development create potential barriers to entry and multiple commercialization routes (manufacturing, licensing, partnerships) that can generate recurring revenue over time.
Bears Say
Persistent Negative Cash FlowOperating and free cash flows are consistently negative, meaning the business is not yet self-funding. Cash burn is sizable relative to the current revenue run-rate, which creates ongoing financing needs, raises dilution risk, and constrains the ability to scale manufacturing or commercialization without external capital.
Very Small Revenue Base & Negative MarginsWith TTM revenue near $0.94M and a recent shift to negative gross margin, the company lacks scale to absorb fixed costs. Deep operating losses relative to sales hinder margin sustainability and raise uncertainty about achieving profitable unit economics without substantial revenue expansion or cost restructuring.
Deep Losses Eroding Returns On EquityPersistent large losses are producing very negative ROE, which can erode shareholder equity and force dilutive financing or asset sales. Even with low leverage, sustained negative profitability limits reinvestment capacity and increases execution risk for commercializing products over the medium term.
Zentek News
ZEN FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was C$0.75 and its highest was C$2.50 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is C$83.70M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Jul 01, 2026 which is in 129 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Feb 17, 2026. The company reported -C$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.023.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 107,306,500 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -C$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.302%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in TSE:ZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth C$62.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.93%
12-Months-Change
Fundamentals
Return on Equity
-52.95%
Trailing 12-Months
Asset Growth
-11.29%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. (ZEN) is a Canadian technology company specializing in advanced materials and innovative solutions for various industries, including healthcare, energy, and environmental sectors. The company is focused on developing and commercializing its proprietary graphene-based technologies, which are designed to enhance the performance and efficiency of products in fields such as air filtration, antimicrobial coatings, and energy storage.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
Quipt Home Medical
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---